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Research
Arsenic exposure impairs development and can
lead to cancer, cardiovascular disease, and dia-
betes [International Agency for Research on
Cancer (IARC) 2004]. The mechanism under-
lying these effects remains unknown. Primarily
because of geologic sources of contamination,
drinking-water arsenic levels are above the cur-
rent recommended maximum contaminant
level of 10 μg/L in several areas of the United
States, including levels exceeding 20 μg/L in
12% of water supplies from surface water
sources in the north central region, and ground-
water sources in the West [Agency for Toxic
Substances and Disease Registry (ATSDR)
2007; Mead 2005]. Approximately 40% of
households in New Hampshire are served by
unregulated private drinking-water wells, and
10% of these wells contain arsenic at levels > 10
μg/L (Karagas et al. 2002; Mead 2005).
Although many laboratory-based animal or
cell-culture studies have investigated the effects
of arsenic exposure on gene expression using
microarray analysis, many of these were con-
ducted on arsenic exposures outside the normal
range of U.S. contamination, and only a few
have studied arsenic-exposed humans (Andrew
et al. 2007; Argos et al. 2006; Lu et al. 2001;
Wu MM et al. 2003). Progress in arsenic
research has been hampered by the wide varia-
tions in its dose–response effects across different
species and cell lines (IARC 2004). Humans
are believed to be more sensitive to the toxic
effects of arsenic than are model organisms;
therefore it is important to understand the
exposure implications on a genomewide scale
(Mead 2005). The ﬁrst two human studies of
arsenic exposure employed smaller arrays repre-
senting < 1,000 genes to examine arsenic-
exposed tissues. Lu et al. (2001) used liver
biopsies from China (n = 6), whereas Wu MM
et al. (2003) used peripheral blood lympho-
cytes from 24 subjects to compare the effects of
low (0–46.4 μg/dL) versus high (46.4–465
μg/dL) blood arsenic levels [normal blood
arsenic levels are around 70 μg/dL (ATSDR
2007)]. Recently, Argos et al. (2006) used
peripheral blood lymphocytes from a popu-
lation of highly exposed individuals from
Bangladesh with skin lesions and the
Affymetrix GeneChip microarray platform to
investigate differentially expressed genes associ-
ated with arsenic exposure. Mean well-water
levels of arsenic in the Bangladesh study were
342.7 μg/L for the high-exposure group
(n = 11) and 39.6 μg/L for the low-exposure
group (n = 5), which is well above the current
maximum contaminant level of 10 μg/L.
Thus, the objective of the present study was
to investigate the effects of arsenic exposure at
levels relevant to North American popula-
tions. We chose high- versus low-arsenic-
exposed groups from a population in New
Hampshire, where the rural landscape results
in 40% of the population consuming drinking
water from unregulated private wells (Karagas
et al. 2002, 2004).
We conducted a microarray-based genome-
wide analysis of expression patterns associated
with internal biomarkers of arsenic exposure in
peripheral blood lymphocytes from the high-
versus low-exposure groups for this population.
Our analysis characterizes the major biologic
functional classes of genes differentially
expressed in arsenic-exposed individuals.
Understanding the affected biologic pathways
will guide investigations of carcinogenic and
pathogenic mechanisms and assist in the devel-
opment of remediation techniques and chemo-
preventive agents for exposed individuals.
Materials and Methods
Subject selection. This project used samples
from an epidemiologic case–control study in
New Hampshire described previously (e.g.,
Karagas et al. 1998, 2004). One of our major
goals of this study was to investigate the blad-
der and nonmelanoma skin cancer risks associ-
ated with arsenic exposure in New Hampshire.
Controls younger than 65 years were selected
using population lists obtained from the New
Hampshire Department of Transportation.
Controls 65 or more years of age were chosen
from data files provided by the Centers for
Medicare and Medicaid Services of New
Hampshire. Subjects were sent an introductory
recruitment letter followed by a phone call to
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BACKGROUND: Arsenic exposure impairs development and can lead to cancer, cardiovascular
disease, and diabetes. The mechanism underlying these effects remains unknown. Primarily because
of geologic sources of contamination, drinking-water arsenic levels are above the current recom-
mended maximum contaminant level of 10 µg/L in the northeastern, western, and north central
regions of the United States.
OBJECTIVES: We investigated the effects of arsenic exposure, deﬁned by internal biomarkers at levels
relevant to the United States and similarly exposed populations, on gene expression. 
METHODS: We conducted separate Affymetrix microarray-based genomewide analyses of expression
patterns. Peripheral blood lymphocyte samples from 21 controls interviewed (1999–2002) as part
of a case–control study in New Hampshire were selected based on high- versus low-level arsenic
exposure levels. 
RESULTS: The biologic functions of the transcripts that showed statistically signiﬁcant abundance dif-
ferences between high- and low-arsenic exposure groups included an overrepresentation of genes
involved in defense response, immune function, cell growth, apoptosis, regulation of cell cycle, T-cell
receptor signaling pathway, and diabetes. Notably, the high-arsenic exposure group exhibited higher
levels of several killer cell immunoglobulin-like receptors that inhibit natural killer cell activity. 
CONCLUSIONS: These ﬁndings deﬁne biologic changes that occur with chronic arsenic exposure in
humans and provide leads and potential targets for understanding and monitoring the pathogenesis
of arsenic-induced diseases. 
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[Online 23 January 2008]]arrange an in-person interview. For this pro-
ject, we selected subjects from a group of 606
controls who were interviewed between 1999
and 2002. The overall study participation rate
was approximately 70% of the controls con-
firmed to be eligible for the study. Of those
from whom we requested samples, the partici-
pation rate was approximately 72% for the
blood draw, 90% for toenail clippings, 95%
for urine collection, and more than 95% for
water. Data on subjects’ exposure history were
available through a personal interview covering
demographic information, history of tobacco
use, and other lifestyle factors. Informed con-
sent was obtained from each participant, and
all procedures and study materials were
approved by the Committee for the Protection
of Human Subjects at Dartmouth College.
Selection of the 21 control subjects (i.e.,
who did not have cancer) who were used for
this present project was based on internal bio-
markers (toenail or urine) and household
drinking-water arsenic exposure levels from
individuals on whom cryopreserved lympho-
cytes were available at the time the project
began. The selected subjects had agreed to
provide a venous blood sample that was
drawn into cell preparation tubes (CPTs)
containing citrate and a lymphocyte isolation
gradient (Becton, Dickinson and Co.,
Franklin Lakes, NJ). Blood tubes were main-
tained at 4°C and sent to the study laboratory
for processing and analysis. No later than
24 hr after the blood draw, lymphocytes col-
lected in CPTs containing sodium citrate
were isolated according to the manufacturer’s
instructions using standard buoyant density
centrifugation methods. After centrifugation,
first plasma was removed, aliquoted, and
frozen at –80°C, then the mononuclear cells
were removed by pipette and cryopreserved
(–120°C) using freezing media at a controlled
rate of 1°C per minute. The viability of the
cells after thawing was assessed to be 98%
using trypan blue, as reported previously for
this method (Wei et al. 1994).
A water sample from the current house-
hold drawn into commercially washed (min-
eral-free) high-density polyethylene bottles
that met U.S. Environmental Protection
Agency standards for water collection
(I-Chem vials; Fisher Scientific, Pittsburgh,
PA) was analyzed for arsenic concentration
using an Agilent 7500c Octopole inductively
coupled plasma mass spectrometer (Agilent
Technologies, Palo Alto, CA) in the
Dartmouth Trace Element Analysis Core
Facility. Toenail clipping samples collected at
the time of interview were analyzed for
arsenic and other trace elements by instru-
mental neutron activation analysis (INAA) at
the University of Missouri Research Reactor,
using a standard comparison approach as
described previously (Cheng et al. 1995). The
detection limit for arsenic measured by INAA
is approximately 0.001 μg/g. First morning
void urine samples were obtained in 100-mL
polypropylene bottles and kept on ice.
Within 6 hr, cooled samples were taken to the
laboratory and kept frozen at –80°C until the
analysis of total arsenic and arsenic species
was performed as described previously (Meza
et al. 2005). The detection limits were
0.42–1.08 μg/L for arsenic compounds.
Individuals from whom we had collected
cryopreserved lymphocyte, drinking-water, and
either toenail or urine samples were candidates
for the microarray project. From this subset, we
first selected individuals for the high-arsenic
group based on arsenic exposure criteria deﬁned
by drinking-water arsenic concentration com-
bined with urinary or toenail arsenic levels as
internal biomarkers of exposure, as detailed
below. We then selected a set of low arsenic
exposure subjects matched for age, sex, and
smoking status. Within the subset selected for
the microarray project, the drinking-water
arsenic levels of the high-exposure group
(n = 11) averaged 32 μg/L (range, 10.4–74.7
μg/L), whereas the levels for the low-exposure
group (n = 10) averaged 0.7 μg/L (range,
0.007–5.3 μg/L). Individuals with inorganic
urinary arsenic levels (overnight > 5 μg/L, spot
> 1 μg/L) or > 0.11 μg/g toenail arsenic were
considered to have high arsenic exposure.
Gene expression analysis. RNA was har-
vested from peripheral blood lymphocytes
using Trizol reagent (Gibco/BRL Life
Technologies, Gaithersburg, MD) followed by
DNase digestion using DNAfree (Ambion
Inc., Austin, TX) according to the manufac-
turer’s instructions and quantitated by spec-
trophotometric absorbance at 260 nm. RNA
quality was evaluated using A260/A280 ratio
(> 1.8) and the RNA 6000 Nano Chips in the
Agilent 2100 Bioanalyzer (Agilent Tech-
nologies). The expression proﬁles were gener-
ated using the Affymetrix GeneChip
Technology Human Genome U133 Plus 2.0
oligonucleotide arrays (Affymetrix, Santa
Clara, CA), which simultaneously tested more
than 47,000 transcripts for each subject on the
integrated GeneChip Instrument System in the
Dartmouth Microarray Core Facility. Our
experiment was performed in compliance with
the Minimum Information About a Micro-
array Experiment (MIAME) checklist for stan-
dardization guidelines for microarray
experiments. Array data from this experiment
will be available on the National Institutes of
Health GEO database or by contacting the
author. Affymetrix chip CEL files were
imported into the statistical programming lan-
guage R and analyzed using the Bioconductor
package “affy” (Gentlemen et al. 2005). Data
were normalized using robust multichip analy-
sis (RMA) implemented with Bioconductor
software (Irizarry et al. 2003) followed by
empirical Bayes adjustment procedures imple-
mented on the R platform, as described previ-
ously (Johnson et al. 2007). Analysis using the
Statistical Analysis of Microarrays (SAM) pack-
age (Stanford University, Stanford, CA;
http://www-stat.stanford.edu/~tibs/SAM) was
performed with a two-class comparison
between the high- versus low-arsenic exposure
groups, deﬁned as described above by drink-
ing-water arsenic concentration combined with
urinary and toenail arsenic levels. We used
1,000 permutations and selected significant
genes with a false discovery rate (FDR) of
< 5% from a delta value of 0.7 to identify sta-
tistically signiﬁcant differences in gene expres-
sion, accounting for multiple comparisons
(Tusher et al. 2001). We constructed a heat
map (Figure 1) for these 259 genes, and their
successful agglomerative hierarchical clustering
into high- and low-arsenic-exposed groups was
assessed via bootstrap evaluation with confi-
dence levels of > 98% [for a complete list, see
Supplemental Material (http://www.ehponline.
org/members/2008/10861/suppl.pdf)]
(Kamimura et al. 2003).
We performed an additional analysis
restricted to a subset of 10 individuals with uri-
nary arsenic exposure data as an internal meas-
ure of very recent arsenic exposure from the
originally selected set of 21 subjects (Biggs et al.
1997). This additional analysis excluded sub-
jects on whom we did not have urinary arsenic
data, because toenail arsenic reflects chronic
exposure (previous 12–18 months) (Slotnick
and Nriagu 2006). Microarray data on subjects
with urinary arsenic levels were normalized
using RMA implemented with Bioconductor
software on the R platform (Irizarry et al.
2003). Subsequent SAM analysis using a delta
of 0.2 yielded 38 modiﬁed genes at or below
5% FDR for the high- versus low-arsenic-expo-
sure groups [for a list, see Supplemental
Material (http://www.ehponline.org/members/
2008/10861/suppl.pdf)].
We selected transcripts for validation by
real-time polymerase chain reaction (PCR)
using independent primer sets based on the
microarray results. TaqMan primer-probe sets
for each selected transcript were obtained
from Applied Biosystems Inc. (Foster City,
CA): perforin 1 (PRF1), interleukin 2 recep-
tor, beta (IL2RB), killer cell immunoglobulin-
like receptor, three domains, long cytoplasmic
tail, 1 (KIR3DL1), and major histocompati-
bility complex (MHC), class II, DR beta 1
(HLA-DRB1). Real-time reverse transcription
(RT)-PCR was performed using the Applied
Biosystems Inc. PRISM sequence detection
system and software. Briefly, total RNA
(1.0 μg) was reverse transcribed using 100 U
Moloney murine leukemia virus reverse tran-
scriptase in a mixture with oligo-dT and
dNTPs according to the instructions provided
with the Omniscript kit (QIAGEN Inc.,
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scribed in a PTC-100 thermocycler (MJ
Research Inc., Watertown, MA) for 60 min at
44°C, and the reaction was terminated by
heating to 95°C for 10 min. Expression of
speciﬁc genes was assessed by real-time PCR
using 10 ng total RNA, 400 nM primers,
200 nM probe, and TaqMan Universal PCR
Master Mix (Applied Biosystems Inc.).
Relative quantitation was performed using a
standard curve consisting of serial dilutions of
pooled sample cDNA from the same source
as the test RNA with each plate. Relative
expression levels of each gene were normal-
ized to the cDNA concentrations and plotted
against the creatinine-normalized urinary
arsenic level.
Biological function analysis. We further
characterized the functional effects of the
arsenic-modified genes by implementing the
Database for Annotation, Visualization, and
Integrated Discovery (DAVID) Gene Ontology
(GO) search engine (http://www.geneontology.
org/GO.tools.microarray.shtml; Dennis et al.
2003). This bioinformatic tool identiﬁes func-
tional processes that are overrepresented by the
modiﬁed genes. Genes with statistically signiﬁ-
cant expression differences were also mapped to
Kyoto Encyclopedia of Genes and Genomes
(KEGG; http://www.genome.jp/kegg/pathway.
html) biopathways, including the natural killer
cell–mediated cytotoxicity pathway, to investi-
gate their systemic roles.
Biologic roles of the arsenic-modiﬁed genes
were then queried against the Pathway Studio
ResNet 5.0 database (Ariadne Genomics,
Rockville, MD). This database catalogs rela-
tionships between biologic entities based on
the published literature and was used to iden-
tify the direct interactions between the arsenic-
modiﬁed genes. These relations are depicted by
colored lines and arrows in Figure 2.
We also implemented the Exploratory
Visual Analysis (EVA) software package to
facilitate graphical interpretation of our
microarray data in the context of biological
information, as described previously (Reif et al.
2005; Reif and Moore 2006). We preﬁltered
the normalized data from all 21 individuals
using the ReliefF algorithm (Kononenko et al.
1997), and the top-ranked 12,484 genes were
queried against KEGG biopathways. This
strategy allowed us to explore broader trends in
the data that may have been missed on the
more restrictive SAM list.
Results
To evaluate the possibility of gene expression
modification by arsenic, we selected subjects
according to individual exposure status from
those who provided a blood sample. The high-
and low-arsenic-exposure groups are compara-
ble for sex (high arsenic: 82% male, 18%
female; low arsenic: 80% male, 20% female)
and age (high arsenic: mean, 66 years; low
arsenic: mean, 67 years). The high-arsenic-
exposure group had a slightly higher propor-
tion of smokers (high arsenic: no, 73%, yes,
27%; low arsenic: no, 90%, yes, 10%). This
selected subset is similar to the population of
total controls for age, sex, and smoking status
(Andrew et al. 2006).
We identiﬁed 259 genes with statistically
signiﬁcant expression differences (high vs. low
arsenic exposure status in 21 individuals) by the
SAM test [Figure 1; Supplemental Material,
Table 1 (http://www.ehponline.org/members/
2008/10861/suppl.pdf)]. The expression of the
statistically signiﬁcant genes reliably reproduced
the dose–response clustering of subjects by
arsenic exposure level (Figure 1, columns).
With the exception of subject 9, all of the indi-
viduals exposed to high arsenic levels clustered
separately (dark gray bars) from those exposed
to low levels (light gray bars). Although there is
some variability, as expected in a study of
humans, the clustering of the rows (genes) on
the heat map reveals distinct patterns of tran-
script abundance between lymphocyte samples
that clearly separate the high- from the low-
arsenic-exposed subjects (between subjects 13
and 17). We also performed a sensitivity analy-
sis by running the algorithm with and without
women or individuals who had a history of
Andrew et al.
526 VOLUME 116 | NUMBER 4 | April 2008 • Environmental Health Perspectives
Figure 1. Heat map of genes with statistically signiﬁcant expression differences by arsenic exposure level.
The rows represent the genes selected by SAM analysis. The heat-map colors depict the gene expression
level from low (black) to high (red). Each column represents an individual (numbered at the bottom) with
either high (dark gray bar at the bottom) or low (light gray) arsenic exposure level. Genes and individuals
were hierarchically clustered by expression level.smoking. The genes with modiﬁed transcript
abundance show similar patterns regardless of
smoking status or sex.
Functional categories of these SAM-
selected significant transcripts detected by
DAVID functional annotation clustering
indicated enrichment (p < 0.05) for genes
involved in defense response (p < 0.001),
immune response (p = 0.003), cell growth
(p = 0.001), signal transduction (p = 0.01),
apoptosis (p = 0.01), regulation of cell cycle
(p = 0.02), JAK-STAT cascade (p = 0.004),
T-cell receptor signaling pathway (p = 0.01),
GTPase activity (p = 0.008), and type 1 dia-
betes mellitus (p = 0.002). The selected tran-
scripts involved in diabetes included PRF1,
HLA-DQA1, HLA-DQB1, SOCS3, HLA-
DPA1, and GZM2. We also saw significant
differences in transcripts involved in the ner-
vous system (e.g., MATK, NCAM1, GPR56,
MEF2C, ZFHX1B) and other aspects of
development (e.g., AES, TAGLN, ARIH2,
WNT10A, MRAS, ITGA6, ANXA2, VAMP5)
[Supplemental Material, Table 1 (http://
www.ehponline.org/members/2008/
10861/suppl.pdf]. In the ubiquitin cycle, we
saw differences between high- and low-arsenic
groups for F-box protein transcripts FBXO32,
FBX03, TRIAD3, and ariadne homolog 2
(ARIH2).
The pathways with the most statistically sig-
niﬁcant level of enrichment and largest number
of modiﬁed transcripts associated with arsenic
exposure were those involved in defense and
immune response (listed in Table 1). These
included induction of many probe sets that
detected various isoforms of the killer cell
immunoglobulin-like receptor that inhibits the
activity of the MHC class I receptor. A number
of the SAM-selected genes that showed
increased or decreased transcript abundance in
lymphocytes from the high- versus low-exposure
groups are part of the natural killer cell cytotoxic
KEGG pathway [Supplemental Material, Figure
1 (http://www.ehponline.org/members/2008/
10861/suppl.pdf)]. Notably, expression of the
killer cell immunoglobulin-like inhibitory recep-
tors (KIR) is increased. Arsenic exposure was
also associated with modiﬁed levels of granzyme
b (GZMB) and PRF1, enzymes that control nat-
ural killer cell–mediated apoptosis. Our data
suggest decreases in defense response genes,
including the heat-shock protein HSPA9B,
CD69, and mucosa associated lymphoid tissue
lymphoma translocation gene 1 (MALT1) asso-
ciated with arsenic exposure. Inflammatory
response pathway members selected in
our analysis included IL2RB, carbohydrate
(N-acetylglucosamine-6-O) sulfotransferase 2
(CHST2), nuclear factor of activated T-cells
(NFATC3), arachidonate 5-lipoxygenase
(ALOX3), and pentraxin-related gene (PTX3).
We also mapped the SAM-selected differ-
entially expressed genes onto a cell diagram
to visualize the common regulators of the
modified transcripts using Pathway Studio
(Figure 2). Color intensity shows the level of
abundance of each transcript (red, increased;
green, decreased) in lymphocytes from the
high-arsenic exposure compared with the
low-arsenic-exposure group. The lines repre-
sent relationships among the top-ranked bio-
logic molecules that have been established by
previous work published in the literature.
Importantly, this diagram helps predict dif-
ferential expression of the genes that may
have profound biologic consequences (i.e., by
modulating protein stability or activation
level) that are not observable in a gene
expression microarray.
Using an alternative analysis strategy to
more broadly characterize arsenic-associated
expression modiﬁcation, we used EVA software
to graphically characterize functions of the top
ranked 12,484 genes selected by ReliefF algo-
rithm. Thus, we are including many genes with
more subtle or less consistent regulation than in
the SAM-selected set. This technique detected
an overrepresentation of genes (Fisher exact
p < 0.05) involved in the KEGG biopathway
and Gene Ontology processes, including 7 in
natural killer cell–mediated cytotoxicity and
cellular defense response, 8 in antigen process-
ing and presentation and immune response, 12
cellular adhesion molecules (CAMs) and cell
adhesion, and 6 in the Wnt signaling pathway
and regulation of transcription. Other high-
ranking but nonsigniﬁcant categories included
regulation of actin cytoskeleton, neuroactive lig-
and–receptor interaction, Jak-STAT signaling,
axon guidance, ABC transporters, peroxisome
proliferator–activated receptor (PPAR) signal-
ing pathway, and type 1 diabetes mellitus.
In addition, we performed an analysis
restricted to the subset of 10 individuals with
data on high versus low urinary arsenic levels.
In this way, we avoid any potential misclassiﬁ-
cation of individuals that could be associated
with relying on home drinking-water arsenic
concentration or toenail levels, which are
longer term biomarkers of exposure than urine.
We compared expression levels for individuals
with a urinary biomarker of very recent high
arsenic exposure versus those with low urinary
arsenic exposure using SAM. We identiﬁed a
total of 38 genes that were signiﬁcantly differ-
ent in those with high versus low urinary
arsenic levels [Supplemental Material, Table 2
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Figure 2. Pathway Studio diagram of common regulators of differentially expressed genes. Genes with
statistically signiﬁcant expression differences were queried against the Pathway Studio ResNet 5.0 database
to identify common regulators. Biological relationships are represented by red arrows for positive effects
and green arrows for negative effects. Genes are represented by colored shapes: those with increased
expression with high arsenic exposure are shown in red; those with decreased expression in response to
high arsenic exposure are shown in green. Other genes that are directly involved in the pathway, but were
not signiﬁcantly modiﬁed at the gene expression level by arsenic exposure status, are shown in gray.Andrew et al.
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Table 1. Immune response genes signiﬁcantly associated with arsenic exposure level.
Gene symbol (LocusLink)/
Probe IDa Gene name Fold change Gene ontology termsa KEGG pathwayb
HLA-DQA1 (3117) major histocompatibility complex, class II, DQ alpha 1
203290_at 3.37 APEA, IR APAP
236203_at 0.38
213831_at 0.31
KIR3DL2 (3812) killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2
207314_x_at 2.25 CDR APAP, NKMC
211688_x_at 1.75
216907_x_at 1.65
207313_x_at 1.45
SH2D1B (117157) SH2 domain containing 1B
1553177_at 2.03 NKMC
KIR3DL1 (3811) killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1
211389_x_at 1.88 IR, NKCA, NRNK, MHCI, HBSI APAP, NKMC
KIR2DL3 (3804) killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3
208179_x_at 1.82 AB, IR APAP, NKMC
KIR2DL1 (3802) killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 1
210890_x_at 1.78 NRNK, HCSI, IR APAP, NKMC
KIR2DL2 (3803) killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2
211397_x_at 1.74 IR APAP, NKMC
PRF1 (5551) perforin 1 (pore forming protein)
1553681_a_at 1.74 CDR, PATH, VICA NKMC
214617_at 1.53
KIR3DL3 (115653) killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 3
216676_x_at 1.68 APAP
KIR2DS5 (3810) killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 5
208203_x_at 1.57 IR, HCSI APAP
RAC2 (5880) rho family, small GTP binding protein Rac2
207419_s_at 1.55 NKMC, BCRS, FCRI, LTM
KIR2DL5A (57292) killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 5A
211410_x_at 1.49 APAP, NKMC
CD247 (919) CD247 molecule
210031_at 1.48 TCRC NKMC, TCRS
KLRF1 (51348) killer cell lectin-like receptor subfamily F, member 1
220646_s_at 1.43 AHR, MHCI
GBP5 (115362) guanylate binding protein 5
238581_at 1.41 IR
KLRK1 (22914) killer cell lectin-like receptor subfamily K, member 1
205821_at 1.38 NKMC
KIR2DL4 (3805) killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4
211242_x_at 1.36 CDR APAP, NKMC
211245_x_at 1.25
208426_x_at 1.24
KIR2DS1 (3806) killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 1
208198_x_at 1.34 IR APAP, NKMC
NFATC3 (4775) nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3
207416_s_at 1.33 INFR NKMC, TCRS, BCRS
DKFZP564J0863 (25923)
224893_at 1.2 IR
TAL1 (6886) T-cell acute lymphocytic leukemia 1
216925_s_at 0.83
SOS1 (6654) son of sevenless homolog 1 (Drosophila)
212780_at 0.83 NKMC, TCRS, FCRI
MALT1 (10892) mucosa associated lymphoid tissue lymphoma translocation gene 1
210017_at 0.82 DR TCRS
HLA-DQB1 (3119) major histocompatibility complex, class II, DQ beta 1
212998_x_at 0.54 IR APAP
211654_x_at 0.51 APAE
212999_x_at 0.35 APEA
209480_at 0.28 MHCII
CDC42 (998) cell division cycle 42 (GTP binding protein, 25 kDa)
214230_at 0.53 MD TCRS, LTM, ECSH
HLA-DPA1 (3113) major histocompatibility complex, class II, DP alpha 1
213537_at 0.49 IR, APEA APAP
PTX3 (5806) pentraxin-related gene, rapidly induced by IL-1 beta
206157_at 0.35 INFR
Gene ontology abbreviations: AB, antigen binding; AHR, antimicrobial humoral response (sensu Vertebrata); APAE, antigen presentation, exogenous antigen; APEA, antigen processing, exoge-
nous antigen via MHC class II; CDR, cellular defense response; DR, defense response; HBSI, human leukocyte antigen-B (HLA-B) speciﬁc inhibitory MHC class I receptor activity; HCSI, HLA-C
speciﬁc inhibitory MHC class I receptor activity; INFR, inﬂammatory response; IR, immune response; MD, macrophage differentiation; MHCI, MHC class I receptor activity; MHCII, MHC class II
receptor activity; NKCA, natural killer cell activation; NRNK, negative regulation of natural killer cell activity; PATH, pathogenesis; TCRC, T-cell receptor complex; VICA, virus-infected cell apop-
tosis. bKEGG pathway abbreviations: APAP, antigen processing and presentation; BCRS, B-cell receptor signaling pathway; ECSH, epithelial cell signaling in Helicobacter pylori infection; FCRI,
Fc epsilon RI signaling pathway; LTM, leukocyte transendothelial migration; NKMC, natural killer cell–mediated cytotoxicity; TCRS, T-cell receptor signaling pathway.
aProbe IDs were obtained from the Affymetrix NetAffx database (http://www.affymetrix.com/analysis/index.affx).(http://www.ehponline.org/members/2008/
10861/suppl.pdf)]. We used DAVID func-
tional annotation clustering to assess the statis-
tically significant overrepresentation of these
urinary arsenic–modified genes by biological
category: natural killer cell–mediated cytotoxic-
ity (p < 0.001), immune response (p < 0.001),
antigen processing and presentation (p <
0.001), and apoptosis (p = 0.009).
Real-time PCR validation using indepen-
dent primer sets selected based on the micro-
array results are shown in Figure 3. Relative
expression levels of each gene in a lymphocyte
sample are plotted against the creatinine-nor-
malized urinary arsenic level for that subject.
Despite substantial variability, there was a
trend toward increased transcript abundance
for PRF1, IL2RB, and KIR3DL1 with increas-
ing urinary arsenic concentration. HLA-DRB1
expression signiﬁcantly decreased with higher
urinary arsenic levels (r2 = 0.8, p < 0.05).
Discussion
Chronic arsenic exposure at levels found in
U.S. drinking water has been associated with
cancer, cardiovascular disease, and diabetes
(Engel et al. 1994; Karagas et al. 2001, 2004;
Meliker et al. 2007; Steinmaus et al. 2003).
Our microarray-based genomewide analyses
detected patterns of decreased/increased tran-
script abundance in peripheral blood lympho-
cytes from the high- versus low-exposure
groups representing North American drinking-
water arsenic levels. The biologic functions of
the transcripts with statistically signiﬁcant dif-
ferences included an overrepresentation of
genes involved in defense response, immune
function, and apoptosis. Although these
observed changes in lymphocytes may be
interpreted as surrogate markers for changes
that occur in other cell types, they also
directly reﬂect biologically important changes
in the blood of arsenic-exposed individuals
that may be directly involved in disease. For
example, inhibition of immune function may
play a role in promoting immune escape and
tolerance of tumors (LeMaoult et al. 2005).
Despite differences in overall arsenic levels
and country of origin among the previously
reported studies of arsenic-exposed human lym-
phocytes, there are similarities in the differen-
tially abundant transcripts between the high-
and low-arsenic-exposed populations. Our data
suggest decreases in defense response genes,
including heat-shock proteins. Similarly, heat-
shock protein HSPA1B/HSP70 expression was
modiﬁed in lymphocytes from arsenic-exposed
individuals from Bangladesh, as well as in sev-
eral animal and cell culture studies, probably in
response to the generation of reactive oxygen
species (Andrew et al. 2003, 2007; Han et al.
2005; Liu et al. 2001). The Bangladesh and
Taiwan studies and our U.S. study all observed
a decrease in inﬂammatory response pathway
members, including interleukins such as IL2R
(Argos et al. 2006) and IL1β (Wu M.M. et al.
2003). Argos et al. (2006) reported differential
expression of USP13 and the ubiquitin-conju-
gating enzyme UBE2E1, and we also saw differ-
ences in several ubiquitin cycle transcripts.
Our human data also strongly support
previous results from animal and in vitro stud-
ies indicating that chronic arsenic exposure
modulates immune function (IARC 2004).
Mice treated with arsenic had increased bacte-
rial load accompanied by decreased adhesion,
chemotactic migration, and phagocytic ability
of splenic macrophages (Lewis et al. 1998).
Exposure to 2 and 10 μg/L arsenic suppressed
innate immune response in a zebraﬁsh model,
increasing pathogen load and reducing respi-
ratory burst activity (Nayak et al. 2007).
In vitro arsenic exposure (< 75 μg/L) inhibited
maturation of monocytes to macrophages by
producing an abnormal nonadhesive macro-
phage and reorganization of the actin cyto-
skeleton. These arsenic-exposed macrophages
had higher granulocyte-macrophage colony-
stimulating factor–stimulated MHC class II
molecule HLA-DR protein levels, and
decreased phagocytic ability (Lemarie et al.
2006; Sakurai et al. 2005, 2006).
We observed decreased abundance of
CD69 in lymphocytes from the high-arsenic
group, an effect that was observed previously
at the protein level in CD4+ and CD8+ lym-
phocytes treated with arsenic in vitro (Conde
et al. 2007; Tenorio and Saavedra 2005). Our
highly exposed lymphocytes also had increased
levels of IL2RB, which is necessary for activa-
tion of STAT5-dependent T-regulatory cell
differentiation (Burchill et al. 2007). Similarly,
Soto-Pena et al. (2006) reported reduced
peripheral blood mononuclear cell mitogenic
response and a modiﬁed CD4/CD8 lympho-
cyte cell ratio in children with high urinary
arsenic levels. Moreover, mice exposed to
50 mg/L arsenite in their drinking water had
inhibited T-lymphocyte proliferation in
response to mitogens (Patterson et al. 2004).
In vitro studies indicated that arsenic delayed
proliferation of T-lymphocytes and modi-
fied DNA synthesis in a biphasic dose-
dependent manner (Galicia et al. 2003; Meng
and Meng 1994).
Natural killer cells act as a first line of
defense in the blood and are also recruited to
mucosal tissues with inflammation or infec-
tion, including the lung (Sentman et al. 2007).
In our study, lymphocytes from the high-
arsenic-exposure group had increased levels of a
number of inhibitory killer cell immunoglobu-
lin-like receptors, as well as the killer cell lectin-
like receptors GZMB, PRF1, and NFATC3
[Table 1; Supplemental Material, Figure 1
(http://www.ehponline.org/members/2008/
10861/suppl.pdf)]. KIR genes are expressed by
natural killer cells as well as memory αBT cell,
serving both innate and adaptive immune
response (Parham 2004). GZMB and PRF1
help the induction of apoptosis via the cyto-
toxic T-lymphocytes or natural killer cells in
cell-mediated immune response (Adrain et al.
2006; Veugelers et al. 2006). GZMB speciﬁ-
cally destabilizes the cell cytoskeleton during
cytotoxic T-lymphocyte and natural killer
cell–mediated cell killing (Adrain et al. 2006).
NFATC3 is a transcription factor involved in
T-cell development that is activated by hypoxia
(Cante-Barrett et al. 2007).
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Figure 3. RT-PCR analysis of gene expression in relation to urinary arsenic (As). The graphs depict the
normalized RT-PCR gene expression versus creatinine-normalized urinary arsenic exposure levels.
(A) PRF1 (r2 = 0.2). (B) IL2RB (r2 = 0.3). (C) HLA-DRB1 (r2 = 0.8). (D) KIR3DL1 (r2 = 0.1). 
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Normalized urinary AsIn addition to the pervasive effects on
immune response pathways, the lymphocytes
from the high-arsenic-exposure group showed
differences in transcripts involved in diabetes
and nervous system development. Arsenic
exposure has been associated with increased dia-
betes mellitus–related mortality in several popu-
lations, including the United States (Chen et al.
2007; Meliker et al. 2007). Similarly, our study
shows differences in transcripts involved in dia-
betes by arsenic exposure status. The high-
arsenic-exposure group also had modiﬁed levels
of several transcripts involved in the nervous
system and other aspects of development, 
supporting associations between arsenic expo-
sure and fetal and early childhood effects
(Hopenhayn et al. 2006; Rahman et al. 2007;
Wasserman et al. 2004). One of our novel ﬁnd-
ings is that lymphocytes from arsenic-exposed
individuals had higher levels of cytochrome
P450 2E1 (CYP2E1), which metabolizes and
bioactivates a number of chemicals by forming
epoxides, including benzene, vinyl chloride,
1,1-dichloroethylene, trichloroethylene, 1,3-
butadiene, acrylonitrile, and acrylamide, and
metabolizes acetaminophen (Ghanayem 2007).
To elucidate common regulators of the dif-
ferentially abundant transcripts in the high-
versus low-arsenic groups, we mapped our
results on a literature-based pathway diagram
(Figure 2). Notably, TP53 regulates intercellu-
lar adhesion molecule 1 (ICAM-1), which con-
trols immune cell migration and adhesion, and
interferon-related developmental regulator 1
(IFRD1/PC4), which regulates p53 transcrip-
tional activity and is required for myoblast dif-
ferentiation, and also inhibits MyoD and
MADS box transcription enhancer factor 2,
polypeptide C (MEF2C) (Batta and Kundu
2007; Gorgoulis et al. 2005; Micheli et al.
2005; Nery et al. 2006). PPARA-α activates
the nuclear hormone receptor nuclear receptor
subfamily 1, group D, member 2 (NR1D2),
blocking signaling from the orphan receptor-α
(ROR-α) that regulates high-density lipopro-
tein cholesterol, lipid homeostasis, and inﬂam-
mation (Ramakrishnan et al. 2005). E1A
binding protein p300 is a common regulator of
the transcription factor PPARA-α and the
transcription factors MEF2C and signal trans-
ducer and activator of transcription 2 (STAT2)
(Bhattacharya et al. 1996; Ma et al. 2005). The
Rho-family small G-protein cell division
cycle 42 homolog (Saccharomyces cerevisiae)
(CDC42), controls progression through the
cell cycle and also helps regulate degradation of
the central carcinogenesis mediator, the epider-
mal growth factor receptor (EGFR) (Wu WJ
et al. 2003). These human data suggest that
future experimental studies of the regulation of
these pathways by arsenic may provide insights
into mechanisms of arsenic toxicity.
One possible limitation of this study is that
the proportion of smokers varies slightly by
arsenic exposure. This difference in smoking
status is not driving the expression of genes
selected for this analysis, because the gene
expression changes are observed regardless of
smoking status. Furthermore, there is abun-
dant evidence that the most important health
effects of arsenic may occur in combination
with smoking (Chen et al. 2004; Rossman
et al. 2002).
Our study is the first to investigate
genomewide gene transcript abundance differ-
ences that occur in individuals exposed to
drinking-water arsenic contamination in the
United States. The modulated pathways,
including defense response, immune function,
cell growth, apoptosis, regulation of cell cycle,
T-cell receptor signaling pathway, and dia-
betes, were consistent with previous reports
from arsenic-exposed populations. Many of the
genes are involved in carcinogenesis, diabetes,
and immunosuppression, which are previously
documented health effects of chronic arsenic
exposure. Future studies are needed to eluci-
date the mechanisms through which chronic
exposure to arsenic modulates expression of the
identified genes, to clarify the direct roles of
changes in the lymphocytes themselves in con-
trast with surrogate changes that also occur in
other tissues, and to understand the health
consequences of these changes. The arsenic-
modulated pathway members identiﬁed in the
pathogenesis of these diseases are potential tar-
gets for mechanistic studies and prophylactic
or chemopreventive treatment and are candi-
dates for biomonitoring of individuals with a
history of arsenic exposure.
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